PMDA drug package insert
カレトラ配合錠
PMDA Prescription drug · アッヴィ合同会社 · package insert Jun 10, 2024
Key facts
| Brand names | カレトラ配合錠 |
|---|---|
| Nonproprietary names | ロピナビル・リトナビル |
| Companies | 製造販売元／アッヴィ合同会社 |
| Product type | Prescription drug |
| Therapeutic category | 抗ウイルス化学療法剤 |
| Therapeutic category codes | 87625 |
| YJ codes | 6250101F1037 |
| Approval numbers | 22100AMX00433000 |
| Package insert edition | 第5版 |
| Package insert date | Jun 10, 2024 |
| PMDA document key | 112130_6250101F1037_2 |
| PMDA company code | 112130 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: